Under the Microscope: Formaldehyde Inhalation Exposure in NHS Pathology Departments

Magdalena Plesa MIM, MSc, DPhil[1] and Richard L. Yates BM BCh, DPhil[2]

1. University of Liverpool Management School, Chatham Street, Liverpool, L69 7ZH
2. Royal Free London NHS Foundation Trust, Department of Cellular Pathology, Pond Street, London, NW3 2QG

Corresponding author: mplesa@liverpool.ac.uk

Objectives

The US Environmental Protection Agency has determined that formaldehyde presents an "unreasonable risk of injury to human health". Occupational exposure studies demonstrate that chronic formaldehyde inhalation is associated with damage to the respiratory, female reproductive, and nervous systems, and is also carcinogenic. The UK long- and short-term work exposure limit (2ppm) is amongst the world's highest and now diverges significantly from recently improved EU regulation (EU long-term exposure limit: 0.3ppm; EU short-term exposure limit: 0.6ppm). We sought to evaluate the formaldehyde monitoring data of NHS cell pathology departments and compare the extent of inhalation exposure to EU and UK work exposure limits.

Methods

Using the Freedom of Information Act (2000), we requested 12 months of formaldehyde inhalation exposure monitoring data from n=121 NHS Trusts.

Results

In total, 1,712,371 formaldehyde inhalation exposure monitoring events were disclosed by n=104 NHS Trusts on behalf of n=117 NHS cell pathology departments. Formaldehyde inhalation exposure is infrequently monitored (once weekly or less at 73% of sites) and EU work exposure limits are regularly breached (95th centile of exposure >0.3ppm at 70% of sites; 95th centile of exposure >0.6ppm at 44% of sites). Over a third (34%) of NHS cell pathology departments had exceeded the UK work exposure limit at least once in the preceding 12 months. Overall, only 11% of NHS cell pathology departments had at least once daily formaldehyde inhalation exposure monitoring demonstrating a 95th centile of exposure lower than the EU long-term work exposure limit.

Conclusions

Urgent national regulatory intervention is warranted to improve the occupational hygiene of NHS cell pathology departments and protect the health of thousands of NHS employees.

What is already known

A substantial body of occupational exposure data shows that formaldehyde inhalation is associated with myriad deleterious health effects on the respiratory, female reproductive, and nervous systems. It is also a human carcinogen. Pathology departments are amongst the riskiest occupational environments for formaldehyde inhalation exposure and therefore require a high standard of governance and infrastructure to adequately protect staff.

What this study adds

We show that formaldehyde inhalation exposure in most NHS cell pathology departments is monitored infrequently and that EU work exposure limits are often breached. Our data raises concern for the health of thousands of NHS employees working in these environments.

How this study might affect research, practice, or policy

Urgent national regulatory intervention is now warranted to improve the occupational hygiene of NHS cell pathology departments. This will require a combination of upgraded infrastructure, more regular personal exposure monitoring, better employee education on basic lab practice and chemical risk, improved access to appropriate personal protective equipment, management accountability for occupational health, and external oversight by the Health and Safety Executive.

Introduction

The US Environmental Protection Agency (EPA) released its final risk evaluation for formaldehyde in December 2024 and determined that it presents an "unreasonable risk of injury to human health".[1] Occupational formaldehyde inhalation causes mild to severe eye and respiratory tract irritation,[2] decreases pulmonary function,[3,4] induces respiratory tract histopathological lesions,[5–7] and increases the prevalence and severity of allergic conditions and asthma.[8,9] Beyond the respiratory system occupational formaldehyde inhalation has been associated with an increased time-to-pregnancy and risk of spontaneous abortion,[10] the motor neuron disease amyotrophic lateral sclerosis,[11–13] and global cognitive impairment.[14] Formaldehyde is also carcinogenic to humans according to the International Agency for Research on Cancer.[15] Sufficient evidence now supports a causal relationship[16] with nasopharyngeal carcinoma,[17] sinonasal carcinoma,[18] and myeloid leukaemia.[19] Hypopharyngeal carcinoma,[20] Hodgkin lymphoma,[21] and multiple myeloma[21] are also associated.

Due to increasing concern of formaldehyde's toxicity, the European Union (EU) Scientific Committee on Occupational Exposure Limits recommended in 2016 that formaldehyde work exposure limits be revised to 0.3ppm (8-hour time-weighted average) and 0.6ppm (15-minute short-term exposure limit).[22] These recommendations were ratified in a 2019 EU mandate[23] that had a mandatory transposition date into EU member state law of July 2021.[24] A transition period for the healthcare sector ended in July 2024.[23] The UK left the EU in 2021 and was not obligated to adopt this improved regulation. The current UK formaldehyde work exposure limit is 2ppm for both long- and short-term exposure and is amongst the world's highest (Fig. 1).[25]

Under UK Classification and Labelling of Chemicals regulations formaldehyde is designated a Class 1B carcinogen.[26] As a result, occupational formaldehyde exposure is subject to strict UK legislation in addition to compliance with the work exposure limit. Regular staff exposure monitoring is mandatory and for control to be considered adequate employers need to demonstrate that exposure is *as low as is reasonably practicable.*[27] That is, that any further reduction in exposure would require disproportionate sacrifice when weighed against the health benefit.[28] Revised EU work exposure limits set a new precedent on what level of formaldehyde exposure should be considered *reasonably practicable* under current UK legislation.

Pathology services in the UK employ over 28,000 people in England alone.[29] Pathology laboratories are amongst the riskiest occupational settings for inhalation exposure to formaldehyde where it is used in a buffered solution (formalin) to preserve human tissue.[30] Deleterious health effects in pathology laboratory workers are already well described,[31] and include DNA damage that may be associated with cancer morbidity.[32–37]

The extent of formaldehyde exposure amongst UK pathology laboratory workers employed by the National Health Service (NHS) has not been investigated previously and is currently unknown. The Freedom of Information Act (2000) allows access to formaldehyde monitoring data where it is held by a public body.[38] This provides a unique opportunity to investigate the extent of formaldehyde exposure in NHS cell pathology departments. Our data provides evidence that formaldehyde exposure is infrequently monitored and poorly controlled at most NHS hospitals and raises serious concern for the health of thousands of NHS employees that now warrants urgent national regulatory intervention.



Figure 1: Comparison of International Formaldehyde Work Exposure Limits (8-hour time-weighted average). OSHA = Occupational Safety and Health Administration. EU = European Union. SCOEL = Scientific Committee on Occupational Exposure Limits. MHTME = Ministry of Health, Treatment and Medical Education. WS = WorkSafe. KOSHA = Korea Occupational Safety and Health Agency. BAG = Bundesamt fur Gesundheit. IFA = Institut fur Arbeitsschutz. RHCA = Regulations for Hazardous Chemical Agents. JSOH = Japan Society for Occupational Health. MINSU = Ministerio de Salud. WHO (World Health Organisation) recommendation represents an indoor air limit and is added for comparison.

Methods

Freedom of Information (2000) Act Request

Under the Freedom of Information Act (2000), we requested formaldehyde inhalation exposure monitoring data from the preceding 12 months from n=121 NHS Trusts in England (n=102), Scotland (n=9), Wales (n=6), and Northern Ireland (n=4). The list of NHS Trusts contacted was intended to be exhaustive.

We asked NHS Trusts to disclose on how many distinct occasions in the preceding 12 months their cell pathology department(s) had recorded formaldehyde airborne concentrations that were (a) >0ppm and ≤0.3ppm, (b) >0.3ppm and ≤0.4ppm, (c) >0.4ppm and ≤0.5ppm, (d) >0.5ppm and ≤0.6ppm, (e) >0.6ppm and ≤0.7ppm, (f) >0.7ppm and ≤0.8ppm, (g) >0.8ppm and ≤0.9ppm, (h) >0.9ppm and ≤1ppm, (i) >1ppm and ≤1.5ppm, (j)>1.5ppm and ≤2ppm and (k) >2ppm. Bin (k) was required to be open-ended to ensure all formaldehyde monitoring data held by an NHS Trust was disclosed.

We also asked how often formaldehyde inhalation exposure was monitored, the total number of times formaldehyde monitoring had been undertaken in the preceding 12 months, and the approximate annual caseload of each department.

The Freedom of Information Act (2000) contains provisions that allow public bodies to refuse access to records if it is felt gathering, reviewing or preparing requested documents would take an excessive amount of time and effort. The Freedom of Information request used in the current study was therefore intended to balance the level of detail required for a worthwhile investigation whilst at the same time avoiding a significant number of NHS Trusts applying an exemption and refusing to disclose data. Further, due to many NHS Trusts relying on paper records to monitor formaldehyde we could not request raw data

as this would have led to many refusals owing to the time needed to scan potentially thousands of documents.

Regular Monitoring of Formaldehyde Inhalation Exposure
The frequency of formaldehyde inhalation exposure regular monitoring was defined as follows: Continuous (at least one monitoring event once-hourly); Daily (at least one monitoring event once-daily); Weekly (at least one monitoring event once-weekly); Monthly (at least one monitoring event 3-weekly); Quarterly/bi-annually (at least one monitoring event 3-monthly); Annually (at least one monitoring event 9-monthly).

Comparison of Formaldehyde Inhalation Exposure in NHS Cell Pathology departments with EU and UK work exposure limits
Formaldehyde inhalation exposure monitoring data can be used as a guide to assess compliance with work exposure limits. The British Occupational Hygiene Society recommend using the 95th centile of exposure in *Testing Compliance with Occupational Exposure Limits for Airborne Substances*.[39] This method is also endorsed by the US Occupational Safety and Health Administration.[40] To this end, for each site the 95th centile of formaldehyde exposure was compared to the EU long-term (0.3ppm) and short-term (0.6ppm), and UK long- and short-term (2ppm), work exposure limits. Sites where the 95th centile of formaldehyde exposure exceeded the permissible limit were considered non-compliant.

Centile estimates of formaldehyde inhalation exposure were calculated using Monte Carlo simulation with a uniform distribution to avoid potential bias from assuming parametric forms. The analysis was performed using Python 3.12 with NumPy and Pandas libraries. The Monte Carlo algorithm proceeded as follows: for each iteration, random samples were drawn uniformly from within each bin according to the observed frequencies, creating a reconstructed dataset. The 50th and 95th centiles of formaldehyde inhalation exposure were then calculated from this reconstructed dataset. This process was repeated for 1,000 iterations to generate a distribution of centile estimates. Point estimates were calculated as the mean of the Monte Carlo iterations, and 95% confidence intervals were determined for each centile estimate using the 2.5th and 97.5th percentiles of the Monte Carlo distribution.

Where the 50th and 95th centiles of formaldehyde inhalation exposure were both estimated to be <0.3ppm the site was assigned a nominal exposure value of 0.15ppm for visualisation purposes. This ensured a conservative methodology was maintained and avoided artefactual over precision when variability of frequency data was very low at sites with lowest exposure.

Combined Assessment of Adequate Monitoring and Control of Formaldehyde Inhalation Exposure
Adequate monitoring and control of formaldehyde exposure was considered where there was (A) at least once-daily formaldehyde inhalation exposure monitoring and (B) a 95th centile of exposure less than 0.3ppm. These criteria ensured a conservative approach to adequacy given that formaldehyde airborne concentrations would be expected to fluctuate significantly within a single day in a pathology laboratory and because the EU long-term work exposure limit is 0.3ppm.

Results

Study population

Overall response rate was 100% (121/121). In total, 86% (104/121) of NHS Trusts were able to disclose a suitable record of formaldehyde monitoring on behalf of n=117 NHS cell pathology departments, and 14% (17/121) of NHS Trusts could not disclose a suitable record of formaldehyde monitoring. NHS Trusts could not disclose suitable data for the following reasons: n=5 NHS Trusts applied Section 12 of the Freedom of Information Act (cost of compliance exceeds the appropriate limit); n=3 NHS Trusts stated they did not have records available to the level of detail requested; n=5 NHS Trusts disclosed incomplete or missing data that precluded analysis; n=2 NHS Trusts only documented formaldehyde monitoring when 2ppm was exceeded which precluded analysis; and n=2 NHS Trusts refused to disclose data as their laboratory was managed by a third party.

Of the n=117 NHS cell pathology departments able to disclose suitable data, 6% (7/117) were specialist hospitals encompassing children's, women's, orthopaedic, and ophthalmologic services. The remainder (94%; 110/117) were non-specialist. The average annual caseload reported by departments with a suitable record of formaldehyde monitoring was 36,976 (range: 1,780 – 99,627).

Regular Monitoring of Formaldehyde Inhalation Exposure

NHS cell pathology departments with a suitable record of formaldehyde inhalation exposure monitoring disclosed a total of 1,712,371 distinct monitoring events across the whole cohort: 17% of sites (20/117) monitored formaldehyde inhalation exposure continuously, 10% of sites (12/117) monitored formaldehyde inhalation exposure daily, 19% of sites (22/117) monitored formaldehyde inhalation exposure weekly, 34% of sites (40/117) monitored formaldehyde inhalation exposure monthly, 15% of sites (18/117) monitored formaldehyde inhalation exposure quarterly/bi-annually, and 4% of sites (5/117) monitored formaldehyde inhalation exposure annually (Fig. 2).

The number of distinct monitoring events disclosed by NHS Trusts varied widely between sites and was related to both the frequency of regular monitoring and the number of areas within each department assessed during monitoring schedules. For departments with continuous monitoring the average number of disclosures was 84,576 ± 32,220 (mean ± SEM). For departments with daily monitoring the average number of disclosures was 721 ± 148 (mean ± SEM). For departments with weekly monitoring the average number of disclosures was 365 ± 182 (mean ± SEM). For departments with monthly monitoring the average number of disclosures was 90 ± 22 (mean ± SEM). For departments with quarterly/bi-annual monitoring the average number of disclosures was 29 ± 7 (mean ± SEM). For departments with annual monitoring the average number of disclosures was 13 ± 6 (mean ± SEM).



Figure 2: Frequency of Regular Monitoring of Formaldehyde Inhalation Exposure in NHS Cell Pathology Departments

Comparison of Formaldehyde Inhalation Exposure in NHS Cell Pathology departments with EU and UK work exposure limits

The average proportion of annual formaldehyde inhalation exposure monitoring events at each site that exceeded the EU long-term work exposure limit (0.3ppm) was 23.7% ± 2.3% (mean ± SEM). The average proportion of formaldehyde inhalation exposure monitoring events at each site that exceeded the EU short-term work exposure limit (0.6ppm) was 8.5% ± 1.2% (mean ± SEM). The average proportion of formaldehyde inhalation exposure monitoring events at each site that exceeded the UK short- and long-term work exposure limit (2ppm) was 1% ± 0.4% (mean ± SEM). More than a third of NHS cell pathology departments (34%; 40/117) had breached the UK work exposure limit at least once in the preceding 12 months.

Estimated 50th and 95th centiles of formaldehyde inhalation exposure are presented in Fig. 3. In summary, 70% (82/117) of NHS cell pathology departments had a 95th centile of formaldehyde inhalation exposure exceeding the EU long-term work exposure limit (0.3ppm), and 44% (51/117) of NHS cell pathology departments had a 95th centile of formaldehyde inhalation exposure exceeding the EU short-term work exposure limit (0.6ppm). Nil (0/117) NHS cell pathology departments had a 95th centile of formaldehyde inhalation exposure that exceeded the UK short- and long-term work exposure limit (2ppm).

To confirm the validity of our findings in the whole cohort, we performed a subgroup analysis restricted to sites with the highest number of distinct monitoring events (continuous or daily monitoring; n=32). In this subgroup, the average proportion of annual formaldehyde inhalation exposure monitoring events at each site that exceeded the EU long-term work exposure limit (0.3ppm) was 23.4% ± 5% (mean ± SEM). The average proportion of formaldehyde inhalation exposure monitoring events at each site that

exceeded the EU short-term work exposure limit (0.6ppm) was 8.3% ± 2.4% (mean ± SEM). The average proportion of formaldehyde inhalation exposure monitoring events that exceeded the UK short- and long-term work exposure limit (2ppm) was 0.3% ± 0.1% (mean ± SEM). The UK short- and long-term work exposure limit (2ppm) was breached at least once in the preceding 12 months at 59% of sites (19/32). The 95th centile of formaldehyde inhalation exposure exceeded the EU long-term work exposure limit (0.3ppm) also at 59% of sites (19/32) and exceeded the EU short-term work exposure limit at 41% of sites (13/32). Nil sites (0/32) had a 95th centile of formaldehyde inhalation exposure that exceeded the UK short- and long-term work exposure limit (2ppm).

Combined Assessment of Adequate Monitoring and Control of Formaldehyde Inhalation Exposure

Of the NHS cell pathology departments that disclosed a suitable record of formaldehyde exposure data, 11% (13/117) had daily or continuous monitoring demonstrating a 95th centile of formaldehyde inhalation exposure lower than the EU long-term work exposure limit (0.3ppm). The average annual caseload of these departments was 24,133 (range: 5,000 – 60,000).



Figure 3: Comparison of Formaldehyde Inhalation Exposure in NHS Cell Pathology Departments with EU and UK Long-Term Work Exposure Limits. The graph depicts the 50th centile (yellow bars) and the distance from the 50th centile to the 95th centile (orange bars) of formaldehyde inhalation exposure for each NHS hospital that disclosed a suitable record of monitoring. Error bars represent the 95% confidence intervals of each centile estimate. The overlaid red horizontal line depicts the EU long-term work exposure limit (0.3ppm). The overlaid broken red line depicts the UK long-term work exposure limit (2ppm). Green bars represent hospitals where both the 50th and 95th centiles of formaldehyde exposure were <0.3ppm. These cases are given a nominal exposure value of 0.15ppm to avoid artefactual over-estimation of centiles in cases with very low frequency variability. Green bars with red strikethroughs represent hospitals where both the 50th and 95th centiles of formaldehyde exposure monitoring were <0.3ppm but that reported infrequent monitoring (once weekly or less).

Discussion

We present a comprehensive assessment of formaldehyde exposure in NHS cell pathology departments throughout the UK using data that is now publicly available and verifiable. Over 1.7 million distinct formaldehyde measurements have been disclosed from 117 NHS hospitals in England, Scotland, Wales, and Northern Ireland covering a period of 12 months. Our data shows that most NHS hospitals monitor formaldehyde exposure infrequently despite handling tens of thousands of specimens annually. Many NHS hospitals have a poor standard of formaldehyde exposure control that regularly exceeds the EU long- and short-term work exposure limits. Our data warrants urgent national regulatory intervention to improve infrastructure and governance in NHS cell pathology departments and protect the health of thousands of NHS employees.

Formaldehyde is a sensory irritant that causes mild to severe symptoms including stinging, burning, itching, watering eyes, rhinitis, sneezing, coughing, sore throat, and bronchial constriction.[41] Controlled human exposure studies have shown that irritant symptoms begin at formaldehyde inhalation of approximately 0.3ppm and increase in severity with airborne concentration.[2] Occupational exposure studies demonstrate that formaldehyde inhalation causes decrements in pulmonary function,[3,4] induces histopathological lesions of the respiratory tract,[5–7] and increases the incidence and severity of allergy and asthma.[8,9] The US EPA has recently defined the lifetime exposure reference concentration for formaldehyde's respiratory system non-cancer effects as 0.007mg/m^3, 357 times lower than the current UK work exposure limit.[41] The toxicity of formaldehyde is not limited to the respiratory tract. Occupational exposure studies have also shown that formaldehyde inhalation is associated with an increased time-to-pregnancy and risk of spontaneous abortion,[10] with the relevant period of formaldehyde exposure potentially extending well before conception.[41] The US EPA lifetime exposure reference concentration for formaldehyde's female reproductive effects is 0.01mg/m^3, 247 times lower than the current UK work exposure limit.[41] Emerging evidence from multiple occupational cohorts has also associated formaldehyde inhalation exposure with the motor neuron disease amyotrophic lateral sclerosis,[11–13] as well as global cognitive impairment.[14]

Formaldehyde is designated a Group 1 carcinogen by the International Agency for Research on Cancer.[15] Multiple human cohort and case-control studies now provide sufficient evidence[16] that formaldehyde inhalation causes nasopharyngeal[17] and sinonasal carcinoma,[18] and myeloid leukaemia.[19] Formaldehyde is also associated with hypopharyngeal carcinoma,[20] Hodgkin lymphoma,[21] and multiple myeloma.[21] Formaldehyde has been shown to be a direct acting genotoxic agent in a variety of *in vitro* systems,[42] in experimental animal models encompassing mice,[43] rats,[44] and monkeys,[45] and in humans.[32–37] Specifically, formaldehyde has been shown to induce in a concentration and duration-dependant manner point mutations,[46] deletions,[46] DNA-DNA[47] and DNA-protein[42] cross-links, DNA mono adducts,[48] chromosomal aberration[35] and micronuclei formation,[34] single-strand[49] and double-strand breaks,[50] sister chromatid exchanges,[51] inhibition of unscheduled DNA synthesis,[49] DNA repair inhibition,[49] and cellular transformation.[52] Aneuploidy in chromosomes 1,5, and 7 in circulating myeloid progenitor cells, a primary target for lymphohematopoietic carcinogenesis, has also been reported[53] as well as disrupted haematopoiesis.[54] Multiple studies have demonstrated genotoxic damage in both buccal cells and peripheral blood leukocytes of pathology lab workers at relatively low exposure concentrations.[32–37]

Taken together, a substantial body of evidence demonstrates that chronic formaldehyde inhalation exposure causes health effects at concentrations well below the UK work exposure limit and at levels detected in many NHS cell pathology departments. Women

of child-bearing age and individuals with pre-existing respiratory disease are likely to be disproportionately affected. Whilst the UK work exposure limit is amongst the world's highest, additional UK legislation should be protecting workers from these hazardous environments. Employers are required to monitor formaldehyde exposure as regularly as any change occurs that would be expected to affect that exposure, and to reduce exposure to *as low as is reasonably practicable*.[27] That is, the level at which any further exposure reduction would require disproportionate sacrifice when weighed against the health benefit.[28] To this end, revised EU work exposure limits set an important new precedent. It is difficult for an employer to argue that the time, effort, and cost required to reduce formaldehyde exposure to below 0.3ppm would require disproportionate sacrifice when this benchmark is already mandated in 27 EU member states. We believe, therefore, that there are strong scientific and regulatory arguments for mandating at least once-daily monitoring of formaldehyde exposure that demonstrates a 95th centile of exposure below 0.3ppm. Our data shows that, currently, 89% of NHS hospitals fail to conform to this standard. The observation that 11% of NHS hospitals are compliant, including large centres handling tens of thousands of cases annually, undermines any argument that such an expectation is unachievable.

Improving the occupational hygiene of NHS pathology departments need not require substantial investment.[55–57] Our data shows large differences in the 50th and 95th centiles of formaldehyde exposure suggesting that it is high-exposure tasks that are poorly controlled and that should be targeted for intervention. It is acknowledged that formaldehyde cannot easily be replaced. Surgical specimens require formaldehyde fixation to prevent putrefaction and preserve tissue morphology such that accurate microscopic analysis can be undertaken. Fixation requires that specimens are left in full contact with formaldehyde for several hours as tissue penetration is slow. Large specimens therefore require immersion in a substantial volume of formaldehyde and assessment of this tissue requires close examination. Tissue that is not processed into slides is disposed of and waste formaldehyde is washed down the sink. Most inhalation exposure to formaldehyde in pathology departments is therefore derived from specimen dissection and specimen disposal that can then contaminate the wider laboratory environment. Our data suggests exposure control during these tasks is currently poorly controlled and should be targeted for improved governance and infrastructure.

Inhalation exposure to formaldehyde in NHS pathology departments is mostly controlled by local exhaust ventilation, with open down-draught tables widely employed on which high-exposure tasks are undertaken. These units provide partial exposure control that is variable, not well-defined, and not apparent to the user in real time. Our data suggests that the current reliance on this infrastructure is not providing a high standard of exposure control in most NHS hospitals. This is likely due to the dilapidated nature of many sites that precludes effective ventilation even when down-draught tables are operating at their full effectiveness.[58] Purpose-built enclosed cabinets with appropriate ventilation and ergonomic capability for safe and effective dissection of large specimens are commercially available and widely used elsewhere.[59] Indeed, UK legislation already mandates the total enclosure of work with formaldehyde where this is reasonably practicable.[60] If enclosed work spaces are combined with more regular and sufficient personal exposure monitoring, better employee education on basic lab practice and chemical risk, improved access to appropriate personal protective equipment, management accountability for occupational health, and external oversight by the Health and Safety Executive, then significant advance can be made to improve the occupational hygiene of NHS pathology departments without the need for disproportionate investment.

Limitations

The data presented in the current study is derived from information disclosed by NHS Trusts under the Freedom of Information Act (2000). It is therefore secondary data that has not been directly collected by the authors. UK employers are mandated to maintain an accurate record of formaldehyde exposure monitoring that is held for at least 5 years. On this basis the data disclosed is reasonably assumed to be robust and reliable. Any discrepancy owing to human error would be expected to be rare and to not overtly affect the findings of the study given the large number of disclosures analysed. It is noted from our findings that monitoring practices vary widely between NHS hospitals and is often infrequent. Whilst intermittent monitoring urges caution in the precise interpretation of data, sporadic measurements that demonstrate elevated exposures are cause for concern regardless. We do not have information regarding the timing, location, laboratory activity level, etc. of when monitoring was undertaken, or the mode of monitoring in most cases. Whilst sporadic formaldehyde monitoring should be undertaken when exposure is expected to be highest, it is recognised that this is unlikely to always be the case. Formaldehyde measurement may, for example, be undertaken when the laboratory is inactive and this would not be apparent in the data collected. It could also be reasonably argued that hospitals able to disclose data in the current study may be those sites with better governance and improved control of formaldehyde exposure than those that were unable, though this remains a hypothetical.

Conclusions

The International Labour Organization, of which the UK is a signatory, added a "safe and healthy working environment" to its fundamental principles and rights at work in 2022.[61] In December 2024, the US EPA released its final risk evaluation for formaldehyde and determined that it presents an "unreasonable risk of injury to human health".[1] The UK has amongst the world's highest formaldehyde work exposure limits.[25] Nonetheless, the requirement for regular staff exposure monitoring demonstrating formaldehyde inhalation exposure is *as low as is reasonably practicable* should be protecting employees.[27] In practice this legislation seems poorly understood. Our data provides evidence that most NHS cell pathology departments monitor formaldehyde exposure infrequently and that staff are being exposed to inhalation exposures associated with deleterious health effects. The relevance of our data is, however, not limited to pathology departments. Industries with occupational exposure to formaldehyde also include manufacturing, construction, and numerous others that employ many tens of thousands of people in the UK. Improved epidemiological studies that examine health outcomes in these environments are now desperately needed alongside urgent regulatory intervention to proactively protect the health of people working with formaldehyde.

Contributions
MP and RLY contributed equally to the manuscript

Acknowledgments
The authors wish to thank Dr Christopher Partlett (Assistant Professor of Medical Statistics and Clinical Trials, University of Nottingham, UK) for his assistance with the statistical analyses used in this manuscript.

Funding
Not applicable

Competing interests
None declared

Patient Consent for Publication
Not applicable

Ethics Approval
Not applicable

Data Availability Statement
Data disclosed under the Freedom of Information Act (2000) is publicly available.

References

1. US Environmental Protection Agency. Risk Evaluation for Formaldehyde Available from: https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-evaluation-formaldehyde. 2024.

2. Lang I, Bruckner T, Triebig G. Formaldehyde and chemosensory irritation in humans: a controlled human exposure study. *Regul Toxicol Pharmacol RTP*. 2008;50:23–36.

3. Alexandersson R, Hedenstierna G. Pulmonary function in wood workers exposed to formaldehyde: a prospective study. *Arch Environ Health*. 1989;44:5–11.

4. Uthiravelu P, Saravanan A, Kumar CK, Vaithiyanandane V. Pulmonary function test in formalin exposed and nonexposed subjects: A comparative study. *J Pharm Bioallied Sci*. 2015;7:S35–S39.

5. Edling C, Hellquist H, Odkvist L. Occupational exposure to formaldehyde and histopathological changes in the nasal mucosa. *Br J Ind Med*. 1988;45:761–765.

6. Holmström M, Wilhelmsson B, Hellquist H, Rosén G. Histological changes in the nasal mucosa in persons occupationally exposed to formaldehyde alone and in combination with wood dust. *Acta Otolaryngol (Stockh)*. 1989;107:120–129.

7. Boysen M, Zadig E, Digernes V, Abeler V, Reith A. Nasal mucosa in workers exposed to formaldehyde: a pilot study. *Br J Ind Med*. 1990;47:116–121.

8. Sakamoto T, Doi S, Torii S. Effects of formaldehyde, as an indoor air pollutant, on the airway. *Allergol Int*. 1999;48:151–160.

9. Lam J, Koustas E, Sutton P, et al. Exposure to formaldehyde and asthma outcomes: A systematic review, meta-analysis, and economic assessment. *PloS One*. 2021;16:e0248258.

10. Taskinen HK, Kyyrönen P, Sallmén M, et al. Reduced fertility among female wood workers exposed to formaldehyde. *Am J Ind Med*. 1999;36:206–212.

11. Weisskopf MG, Morozova N, O'Reilly EJ, et al. Prospective study of chemical exposures and amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry*. 2009;80:558–561.

12. Roberts AL, Johnson NJ, Cudkowicz ME, Eum K-D, Weisskopf MG. Job-related formaldehyde exposure and ALS mortality in the USA. *J Neurol Neurosurg Psychiatry*. 2016;87:786–788.

13. Seals RM, Kioumourtzoglou M-A, Gredal O, Hansen J, Weisskopf MG. Occupational Formaldehyde and ALS. *Eur J Epidemiol*. 2017;32:893–899.

14. Letellier N, Gutierrez L-A, Pilorget C, et al. Association Between Occupational Exposure to Formaldehyde and Cognitive Impairment. *Neurology*. 2022;98:e633–e640.

15. Protano C, Buomprisco G, Cammalleri V, et al. The Carcinogenic Effects of Formaldehyde Occupational Exposure: A Systematic Review. *Cancers*. 2021;14:165.

16. National Academies of Sciences, Engineering, and Medicine; Division on Earth and Life Studies; Board on Environmental Studies and Toxicology; Committee on Review of EPA's 2022 Draft Formaldehyde Assessment. Review of EPA's 2022 Draft Formaldehyde Assessment. Washington (DC): National Academies Press (US) Available from: http://www.ncbi.nlm.nih.gov/books/NBK600424/. 2023.

17. Vaughan TL, Stewart PA, Teschke K, et al. Occupational exposure to formaldehyde and wood dust and nasopharyngeal carcinoma. *Occup Environ Med*. 2000;57:376–384.

18. Luce D, Leclerc A, Bégin D, et al. Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. *Cancer Causes Control CCC*. 2002;13:147–157.

19. Schwilk E, Zhang L, Smith MT, Smith AH, Steinmaus C. Formaldehyde and leukemia: an updated meta-analysis and evaluation of bias. *J Occup Environ Med*. 2010;52:878–886.

20. Laforest L, Luce D, Goldberg P, et al. Laryngeal and hypopharyngeal cancers and occupational exposure to formaldehyde and various dusts: a case-control study in France. *Occup Environ Med*. 2000;57:767–773.

21. Beane Freeman LE, Blair A, Lubin JH, et al. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort. *J Natl Cancer Inst*. 2009;101:751–761.

22. Directorate-General for Employment, Social Affairs and Inclusion (European Commission), Klein CL, Nielsen GD, Johanson G, Bolt HM, Papameletiou D. SCOEL/REC/125 formaldehyde: recommendation from the Scientific Committee on Occupational Exposure Limits. Publications Office of the European Union Available from: https://data.europa.eu/doi/10.2767/399843. 2016.

23. Directive - 2019/983 - EN - EUR-Lex Available from: https://eur-lex.europa.eu/eli/dir/2019/983/oj/eng.

24. EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work - EU monitor Available from: https://www.eumonitor.eu/9353000/1/j9vvik7m1c3gyxp/vkzpoa5hnnyc?utm_source=chatgpt.com.

25. EH40/2005 workplace exposure limits: containing the list of workplace exposure limits for use with the Control of Substances Hazardous to Health Regulations 2002 (as amended). Fourth edition. London: TSO; 2020.

26. The GB mandatory classification and labelling list (GB MCL List) - HSE Available from: https://www.hse.gov.uk/chemical-classification/classification/mcl-list.htm.

27. The Control of Substances Hazardous to Health Regulations 2002, Section 7(7)(c)(ii) Available from: https://www.legislation.gov.uk/uksi/2002/2677/regulation/7.

28. Health and Safety Executive HSE. L5 Control of Substances Hazardous to Health: The Control of Substances Hazardous to Health Regulations 2002. Approved Code of Practice and Guidance, L5. Norwich: The Stationery Office Ltd; 2013.

29. Satta G, Edmonstone J. Consolidation of pathology services in England: have savings been achieved? *BMC Health Serv Res*. 2018;18:862.

30. Cammalleri V, Pocino RN, Marotta D, et al. Occupational scenarios and exposure assessment to formaldehyde: A systematic review. *Indoor Air*. 2022;32:e12949.

31. Kangarlou MB, Dehdashti A, Saleh E. A detailed methodology for estimating health-related hazards of workplace exposure to indoor formaldehyde vapours. *MethodsX*. 2024;13:102937.

32. Costa S, Coelho P, Costa C, et al. Genotoxic damage in pathology anatomy laboratory workers exposed to formaldehyde. *Toxicology*. 2008;252:40–8.

33. Costa S, Pina C, Coelho P, et al. Occupational exposure to formaldehyde: genotoxic risk evaluation by comet assay and micronucleus test using human peripheral lymphocytes. *J Toxicol Environ Health A*. 2011;74:1040–51.

34. Ladeira C, Viegas S, Carolino E, Prista J, Gomes MC, Brito M. Genotoxicity biomarkers in occupational exposure to formaldehyde—The case of histopathology laboratories. *Mutat Res Toxicol Environ Mutagen*. 2011;721:15–20.

35. Santovito A, Schilirò T, Castellano S, et al. Combined analysis of chromosomal aberrations and glutathione S-transferase M1 and T1 polymorphisms in pathologists occupationally exposed to formaldehyde. *Arch Toxicol*. 2011;85:1295–1302.

36. Bouraoui S, Mougou S, Brahem A, et al. A Combination of Micronucleus Assay and Fluorescence In Situ Hybridization Analysis to Evaluate the Genotoxicity of Formaldehyde. *Arch Environ Contam Toxicol*. 2013;64:337–344.

37. Costa S, Carvalho S, Costa C, et al. Increased levels of chromosomal aberrations and DNA damage in a group of workers exposed to formaldehyde. *Mutagenesis*. 2015;30:463–73.

38. Freedom of Information Act 2000 Available from: https://www.legislation.gov.uk/ukpga/2000/36/contents.

39. British Occupational Hygiene Society. Testing Compliance with Occupational Exposure Limits for Airbourne Substances (2022) Available from: https://www.bohs.org/app/uploads/2022/11/Testing-Compliance-with-OELs-for-Airborne-Substances-2022.pdf. 2022.

40. 1910.1048 App B - Sampling strategy and analytical methods for formaldehyde | Occupational Safety and Health Administration Available from: https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1048AppB.

41. US EPA NCFEA. IRIS Toxicological Review of Formaldehyde (Inhalation) (Final Report, 2024). *US EPA* Available from: https://iris.epa.gov/document/&deid%3D361799. 2024.

42. Wilkins RJ, Macleod HD. Formaldehyde induced DNA—Protein crosslinks in *Escherichia coli*. *Mutat Res Mol Mech Mutagen*. 1976;36:11–16.

43. Ye X, Ji Z, Wei C, et al. Inhaled formaldehyde induces DNA–protein crosslinks and oxidative stress in bone marrow and other distant organs of exposed mice. *Environ Mol Mutagen*. 2013;54:705–718.

44. Jiménez-Villarreal J, Betancourt-Martínez ND, Carranza-Rosales P, et al. Formaldehyde induces DNA strand breaks on spermatozoa and lymphocytes of Wistar rats. *Cytol Genet*. 2017;51:65–73.

45. Casanova M, Morgan K, Steinhagen W, Everitt J, Popp J, Heck H. Covalent binding of inhaled formaldehyde to DNA in the respiratory tract of rhesus monkeys: pharmacokinetics, rat-to-monkey interspecies scaling, and extrapolation to man. *Fundam Appl Toxicol Off J Soc Toxicol*. 1991;17:409–28.

46. Crosby RM, Richardson KK, Craft TR, Benforado KB, Liber HL, Skopek TR. Molecular analysis of formaldehyde-induced mutations in human lymphoblasts and e. coli. *Environ Mutagen*. 1988;12:155–166.

47. Liu Y, Li C, Lu Z, Ding S, Yang X, Mo J. Studies on formation and repair of formaldehyde-damaged DNA by detection of DNA-protein crosslinks and DNA breaks. *Front Biosci J Virtual Libr*. 2006;11:991–7.

48. Kawanishi M, Matsuda T, Yagi T. Genotoxicity of formaldehyde: molecular basis of DNA damage and mutation. *Front Environ Sci*. 2014; 2:36.

49. Grafstrom RC, Fornace Jr, Autrup H, Lechner JF, Harris CC. Formaldehyde damage to DNA and inhibition of DNA repair in human bronchial cells. *Science*. 1983;220:216–8.

50. Nadalutti CA, Stefanick DF, Zhao M-L, et al. Mitochondrial dysfunction and DNA damage accompany enhanced levels of formaldehyde in cultured primary human fibroblasts. *Sci Rep*. 2020;10:1–13.

51. Merk O, Speit G. Significance of formaldehyde-induced DNA-protein crosslinks for mutagenesis. *Environ Mol Mutagen*. 1998;32:260–8.

52. Chen D, Fang L, Mei S, et al. Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells. *Environ Health Perspect*. 2017;125:097019.

53. Lan Q, Smith MT, Tang X, et al. Chromosome-wide aneuploidy study of cultured circulating myeloid progenitor cells from workers occupationally exposed to formaldehyde. *Carcinogenesis*. 2015;36:160–167.

54. Zhang L, Tang X, Rothman N, et al. Occupational Exposure to Formaldehyde, Hematotoxicity, and Leukemia-Specific Chromosome Changes in Cultured Myeloid Progenitor Cells. *Cancer Epidemiol Biomarkers Prev*. 2010;19:80–88.

55. d'Ettorre G, Caroli A, Mazzotta M. Minimizing formaldehyde exposure in a hospital pathology laboratory. *WORK*. 2021;69:209–213.

56. Scheepers PTJ, Graumans MHF, Beckmann G, et al. Changes in Work Practices for Safe Use of Formaldehyde in a University-Based Anatomy Teaching and Research Facility. *Int J Environ Res Public Health*. 2018;15:2049.

57. Ogawa M, Kabe I, Terauchi Y, Tanaka S. A strategy for the reduction of formaldehyde concentration in a hospital pathology laboratory. *J Occup Health*. 2019;61:135–142.

58. Royal College of Pathologists. Spending Review 2025 Available from: https://www.rcpath.org/static/8f6d10dd-de58-4ff5-bd339bf4999fdcbc/RCPath-submission-to-the-spending-review-2025.pdf. 2025.

59. Dugheri S, Massi D, Mucci N, Berti N, Cappelli G, Arcangeli G. How improvements in monitoring and safety practices lowered airborne formaldehyde concentrations at an Italian university hospital: a summary of 20 years of experience. *Arch Ind Hyg Toxicol*. 2020;71:178–189.

60. The Control of Substances Hazardous to Health Regulations 2002, Section 7(5)(a) Available from: https://www.legislation.gov.uk/uksi/2002/2677/regulation/7.

61. Joaquim Pintado Nunes, Shengli Niu, Grace Monica Halim, Dafne Papandrea, Andreas Hoibl. Safe and Healthy Working Environments For All. International Labour Organization (2023).